Details of the Drug Combinations

General Information of This Drug (ID: DME78OA)

• Drug Name: Biperiden (DME78OA)
• Synonyms: Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol

Indication

Parkinson disease; ICD 11: 8A00.0; Status: Approved [1]; Parkinsonian disorder; ICD 11: N.A.; Status: Approved [2]; Postencephalitic Parkinson disease; ICD 11: N.A.; Status: Approved [2]

• Therapeutic Class: Antiparkinson Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

14 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atovaquone + Biperiden	DCUEFAI	Atovaquone	Hepatoblastoma (Cell Line: HB3)	[3]
Biperiden + Clindamycin	DC68P2I	Clindamycin	DD2 (Cell Line: DD2)	[3]
Biperiden + Lumefantrine	DC6RIBT	Lumefantrine	DD2 (Cell Line: DD2)	[3]
Biperiden + Panobinostat	DC1K3YB	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Biperiden + Piperaquine	DCTPHQF	Piperaquine	DD2 (Cell Line: DD2)	[3]
Biperiden + Mefloquine	DCSYD64	Mefloquine	DD2 (Cell Line: DD2)	[3]
Biperiden + Clindamycin	DCEQX0R	Clindamycin	Hepatoblastoma (Cell Line: HB3)	[4]
Biperiden + Ruxolitinib	DC0Z7YG	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
Biperiden + Lumefantrine	DC5ZOTR	Lumefantrine	Hepatoblastoma (Cell Line: HB3)	[4]
Biperiden + Chloroquine	DC1WW0H	Chloroquine	Hepatoblastoma (Cell Line: HB3)	[4]
Biperiden + Quinine	DCB5OQI	Quinine	Hepatoblastoma (Cell Line: HB3)	[4]
Biperiden + Piperaquine	DCD4W8U	Piperaquine	Hepatoblastoma (Cell Line: HB3)	[4]
Biperiden + Pyronaridine	DCPQ2S3	Pyronaridine	Hepatoblastoma (Cell Line: HB3)	[4]
NVP-AUY922 + Biperiden	DC0PU39	NVP-AUY922	DD2 (Cell Line: DD2)	[3]

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Biperiden + Caffeine	DC76NZW	Caffeine	Cocaine Dependence	[5]
Biperiden + Caffeine	DCZ0DFM	Caffeine	Cocaine Related Disorders	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Biperiden FDA Label
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] ClinicalTrials.gov (NCT00495183) Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence
• [6] ClinicalTrials.gov (NCT00495092) Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients